CD36 Mutation Profiling for African-Ancestry DCM Prognosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved technologies to diagnose, prognose, and treat dilated cardiomyopathy (DCM) and heart failure, particularly in individuals of African ancestry, as existing methods have been limited by the lack of genetic data from this population and the disproportionate risk they face.
Innovation Solution
Methods and compositions for detecting CD36 gene variants, including sequencing and amplifying nucleic acids to assess CD36 protein expression or function, which can predict prognosis and response to therapies, and administering targeted pharmacological agents based on CD36 mutation status.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If genetic studies focus on European ancestry populations, then genetic variants can be identified more easily, but the applicability to African ancestry populations is limited
Solution Approach 1:
The patent applies local quality by developing population-specific genetic profiles for African ancestry individuals. Instead of using a universal genetic model derived from European populations, the invention creates tailored diagnostic and prognostic tools that account for the unique genetic architecture, allele frequencies, and risk variants specific to African ancestry populations, thereby improving both measurement precision and population applicability simultaneously
2Reliability
If CD36 protein expression is reduced, then disease risk increases in African ancestry individuals, but standard therapies may not be effective
Solution Approach 1:
The patent applies preliminary action by identifying CD36 expression status and genetic variants before initiating standard heart failure therapies. The invention enables pre-treatment genetic screening and risk stratification, allowing clinicians to identify patients with CD36-related DCM who are likely to respond poorly to conventional therapies, thereby preventing wasteful treatment attempts and guiding early intervention with targeted approaches
3Productivity
If personalized therapy based on CD36 status is implemented, then treatment outcomes improve, but diagnostic complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the diagnostic and therapeutic process into distinct modular steps: (1) genetic screening for CD36 variants, (2) CD36 protein expression assessment, (3) risk stratification based on combined findings, and (4) tailored therapy selection. This segmented approach breaks down the complex personalized medicine paradigm into manageable, sequential components that can be implemented systematically in clinical practice
Data Source
AI summary
Provided herein are methods and compositions for the diagnosis, prognosis, and treatment of dilated cardiomyopathy (DCM) and heart failure (HF). In particular, provided are methods and compositions for detecting a loss-of-function mutation in the CD36 gene. Provided are methods of determining the likelihood that a subject will respond to a treatment for DCM or HF, based on the identification of a CD36 mutation in a sample from the subject.